Dabrafenib and trametinib prices in China

Dabrafenib and trametinib are two drugs that are widely used to treat certain types of cancer and are often used together to make treatment more effective.

Both trametinib and dabrafenib have been launched in China and are included in medical insurance. Patients can purchase them domestically, and the prices are about each more than 10,000 yuan. However, patients still need to consult the local hospital pharmacy for specific costs for accurate information. The price of trametinib abroad is much lower, mainly due to the fact that there are many generic drug options on the market, especially the generic drugs produced in Laos, which cost only about one to two thousand yuan, which is far lower than the domestic price level. Dabrafenib, which is relatively cheap abroad, is mainly a generic drug, mainly a Laotian generic drug. The price is about two to three thousand yuan, which is much cheaper than domestically.

Dabrafenib is a BRAF (B type lymphoma kinase) inhibitor, primarily used to treat patients with BRAF V600 mutated malignant melanoma and BRAF V600E mutated avesicular thyroid cancer. It prevents the growth and spread of cancer cells by inhibiting the activity of BRAF kinase, thereby prolonging the survival of patients.

Trametinib is aMEK (mitogen-activated protein kinase) inhibitor that acts on the signaling pathways within cancer cells and blocks the signal transmission required for cell proliferation and survival. Trametinib is commonly used in combination with dabrafenib for the treatment of BRAF V600 mutated malignant melanoma and BRAF V600E mutated avesicular thyroid cancer.

The combined use of these two drugs can work synergistically to improve the inhibitory effect on cancer cells, thus prolonging the patient's survival. Some clinical trials have shown that the combination of dabrafenib and trametinib can significantly improve survival and relieve symptoms compared with monotherapy in patients with malignant melanoma and avesicular thyroid cancer.